Zydus, XOMA enter into licensing agreement for IL-2-Based Immuno-Oncology Therapy Medical Dialogues Bureau11 March 2020 3:30 AM GMTAhmedabad, Emeryville: Zydus Cadila and XOMA Corporation have announced they have entered into a licensing agreement to advance an IL-2-based immuno-on...
AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial Medical Dialogues Bureau10 March 2020 4:00 AM GMTUSA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not me...
AbbVie gets positive CHMP Opinion for VENCLYXTO for Leukemia patients Medical Dialogues Bureau8 Feb 2020 4:30 AM GMTNew Delhi: AbbVie , a research-based global biopharmaceutical company, announced recently that the Committee for Medicinal Products for Human Use (CHMP...
Shilpa Medicare launches breakthrough therapy lenvatinib mesylate under brand Lenshil in India MD bureau3 Feb 2020 7:52 AM GMT Shilpa Medicare shall launch lenvatinib, at a breakthrough price which is over 50% lower than the existing brand available in India. Prior to the lau...
Roche provides update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer MD bureau27 Jan 2020 8:52 AM GMTBasel: Roche has announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatmen...
Johnson & Johnson misses revenue estimates as blockbuster drugs disappoint Medical Dialogues Bureau24 Jan 2020 8:32 AM GMTUS: Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer...
Drugmajors slash prices by 53pc for China bulk-buy program eligibility Medical Dialogues Bureau20 Jan 2020 4:30 AM GMTBeijing: Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest biddin...
ProBioGen, Lava Therapeutics ink agreement for Novel Bispecific Molecule Medical Dialogues Bureau20 Jan 2020 4:15 AM GMTNew Delhi: ProBioGen AG and Lava Therapeutics B.V. announced the closing of a cell line development and manufacturing agreement for Lava's novel bispec...
USFDA issues warning letter to Rajasthan based homeopathic firm and 3 others Farhat Nasim3 April 2019 3:55 AM GMTNew Delhi: The U.S. Food and Drug Administration (USFDA) recently posted warning letters to four companies producing homoeopathic drug products for...
